News & Updates
Filter by Specialty:
Overall survival in metastatic renal cell carcinoma differs by race, gender, treatment
Among patients with metastatic renal cell carcinoma, there are multiple factors that affect overall survival, including race, gender, treatment, and socioeconomic factors, as reported in a study.
Overall survival in metastatic renal cell carcinoma differs by race, gender, treatment
01 Dec 2021
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
Fusion biopsy with magnetic resonance imaging and ultrasonography (MRI/US) is an efficient method of detecting clinically significant prostate cancer (csPCa) in biopsy-naïve men with prostate specific antigen (PSA) levels 4–10 ng/mL, a new study has found.
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
19 Nov 2021
Low carbohydrate diet lowers risk of MetS, remnant cholesterol in prostate cancer
A low carbohydrate diet (LCD) may substantially reduce the risk of metabolic syndrome (MetS) and remnant cholesterol in patients with prostate cancer, a recent study has shown.
Low carbohydrate diet lowers risk of MetS, remnant cholesterol in prostate cancer
16 Nov 2021
Dose-reduced ARPI leads to inferior survival in CRPC patients
Reduced-dose treatment with androgen receptor pathway inhibitors (ARPI) lead to poorer oncological outcomes relative to full-dose regimens in castration-resistant prostate cancer (CRPC), a recent study has found.
Dose-reduced ARPI leads to inferior survival in CRPC patients
09 Nov 2021
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
Use of the oral antiandrogen chlormadinone at a low dose led to improvements in persistence rate of active surveillance (AS), PSA* and testosterone levels and prostate volume, and quality of life (QoL) in men with low-risk prostate cancer (PCa), the PROSAS study has shown.
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
05 Nov 2021
RS-RARP confers better continence outcomes than conventional RARP
In prostate cancer patients, retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) yields better continence outcomes compared with conventional RARP, a recent study has found.
